HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van Albada, M. E. Articles by Schoemaker, R. G. Search for Related Content PubMed PubMed Citation Articles by van Albada, M. E. Articles by Schoemaker, R. G.

Effects of erythropoietin on advanced pulmonary vascular remodelling

¹ Dept of Paediatrics, Division of Paediatric Cardiology, Beatrix Children's Hospital, and Depts of ² Cardiology, ³ Anaesthesiology, and ⁴ Experimental Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

CORRESPONDENCE: M. E. van Albada, Beatrix Children's Hospital, University Medical Center Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands. Fax: 31 503614235. E-mail: m.e.van.albada{at}bkk.umcg.nl

Keywords: Heart failure, histopathology, pulmonary circulation, ventricular function

Received: March 26, 2007
Accepted September 10, 2007

Erythropoietin (EPO) mobilises endothelial progenitor cells and promotes neovascularisation in heart failure. The present authors studied the effects of EPO on pulmonary vascular and cardiac remodelling in a model for flow-associated pulmonary arterial hypertension (PAH).

PAH was induced in adult male Wistar rats by the injection of monocrotaline combined with an abdominal aortocaval shunt 1 week later (PAH or experimental group). Immediately afterwards, rats were randomised into those who received treatment with EPO (PAH+EPO group) and controls. Pulmonary and systemic haemodynamics, and right ventricular and pulmonary vascular remodelling were evaluated 3 weeks later.

Vascular occlusion of the intra-acinar pulmonary vessels (13.4±0.7 versus 16.7±1.3% in PAH+EPO and PAH, respectively) and medial wall thickness of the pre-acinar arteries (wall-to-lumen ratio 0.13±0.01 versus 0.17±0.01 in PAH+EPO and PAH, respectively) decreased after treatment with EPO. Moreover, right ventricular capillary density was increased by therapy (2,322±61 versus 2,100±63 capillaries·mm^–2 in PAH+EPO and PAH, respectively). Increased mean pulmonary arterial pressure and decreased right ventricular contractility in the model were not altered by EPO treatment.

In this rat model of flow-associated pulmonary arterial hypertension, erythropoietin treatment beneficially affected pulmonary vascular and cardiac remodelling. These histopathological effects were not accompanied by significantly improved haemodynamics.